Investor Relations
|
MNTA - (NASDAQ)
$15.19
+ 0.06
|
Jan 27, 2012 4:00 PM ET |
Momenta Pharmaceuticals is a biotechnology company based in Cambridge, MA focused on the development of complex generics, follow-on biologics and novel drugs. In July 2010, the Company's lead product, enoxaparin sodium injection, (developed with collaboration partner Sandoz) was approved as the first generic version of Lovenox®. The Company's development pipeline includes a generic version of Copaxone, also partnered with Sandoz, follow-on biologic candidates, M118, a rationally designed low molecular weight heparin with improved therapeutic potential, and M402, a heparin-based oncology candidate in preclinical development.
View Annual Report and Proxy Material
Recent Releases
Jan 26, 2012
Momenta Pharmaceuticals Motion for Preliminary Injunction Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd. Stayed
Dec 22, 2011
Momenta to Host Investor Conference Call on December 23, 2011 to Discuss Follow-On Biologics Collaboration With Baxter
View all releases »
